The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.
Michael Bitzer
No relevant relationships to disclose
Marius Horger
No relevant relationships to disclose
Tom M Ganten
No relevant relationships to disclose
Jens T Siveke
No relevant relationships to disclose
Marcus A Woerns
No relevant relationships to disclose
Matthias M. Dollinger
No relevant relationships to disclose
Guido Gerken
No relevant relationships to disclose
Max E. Scheulen
No relevant relationships to disclose
Henning Wege
No relevant relationships to disclose
Edoardo G Giannini
No relevant relationships to disclose
Vincenzo Montesarchio
No relevant relationships to disclose
Anna Mais
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
RĂ¼diger Jankowsky
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Bernhard Hauns
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Bernd Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Ulrich Lauer
No relevant relationships to disclose